Search results
Showing 1711 to 1725 of 2008 results for nice guidelines
Non-cystic fibrosis bronchiectasis: inhaled tobramycin (ES12)
This evidence summary has been updated and replaced by NICE guideline NG117.
Doxylamine/pyridoxine (Xonvea) for treating nausea and vomiting of pregnancy (ES20)
This evidence summary has been updated and replaced by NICE guideline NG201.
Excessive daytime sleepiness in Parkinson's disease: modafinil (ESUOM48)
This evidence summary has been updated and replaced by NICE guideline NG71.
Multiple long-term conditions: falls prevention advice (IND209)
This indicator has been removed following the publication of NICE guideline NG249.
Evidence-based recommendations on eribulin (Halaven) for locally advanced or metastatic (secondary) breast cancer in adults who have had 2 or more courses of chemotherapy.
(which may have led to antimicrobial resistance). In line with the NICE guideline on antimicrobial stewardship: systems and...
SeQuent Please balloon catheter for in-stent coronary restenosis (MTG1)
This medical technologies guidance has been replaced by the recommendations in the NICE guideline on acute coronary syndromes.
Evidence-based recommendations on the EOS 2D/3D imaging system for producing 2D and 3D images of the skeleton.
Schizophrenia: aripiprazole prolonged-release suspension for injection (ESNM39)
This evidence summary has been updated and replaced by the NICE guideline CG178 (published February 2014).
This evidence summary has been updated and replaced by NICE guideline CG113 and subsequent surveillance reviews.
UroShield for preventing catheter-associated urinary tract infections (HTG620)
Evidence-based recommendations on UroShield for preventing catheter-associated urinary tract infections.
This medical technologies guidance has been replaced by the recommendation on cardiac output monitoring in the NICE guideline on perioperative care in adults.
Fruquintinib for previously treated metastatic colorectal cancer (TA1079)
Evidence-based recommendations on fruquintinib (Fruzaqla) for previously treated metastatic colorectal cancer in adults.
Colorectal cancer (advanced) - irinotecan, oxaliplatin and raltitrexed (TA93)
This guidance has been updated and replaced by NICE guideline NG151. The recommendations on raltitrexed have been withdrawn because its use is established clinical practice.
This evidence summary has been withdrawn because licensed products are now available and the off-label indication has been replaced by NICE guideline NG71.